Core Insights - Victory Square Technologies Inc. reported its financial results for Q3 and nine months ended September 30, 2025, highlighting significant developments across its various platforms, including digital health, biotech, pet wellness, climate tech, and immersive technology [1][4]. Financial Highlights - For Q3 2025, the company achieved adjusted revenue of $12.83 million and GAAP revenue of $10.52 million, with a gross margin of $2.33 million and adjusted EBITDA of $1.26 million [8]. - For the nine months ended September 30, 2025, adjusted revenue reached $26.71 million and GAAP revenue was $20.44 million [8]. Portfolio & Strategic Update - Hydreight Technologies, the flagship digital health subsidiary, continued to drive operational performance, recognized as one of the fastest-growing companies in North America [5][6]. - Hydreight's strategic positioning includes a focus on high-growth health segments such as GLP-1 therapies and hormone optimization, supported by a robust compliance infrastructure [10]. - The company launched a $10 million accelerator to incubate direct-to-consumer health companies scaling on the VSDHOne platform [16]. Digital Health Initiatives - Victory Square supports various digital health platforms, including telehealth and diagnostics, aimed at enhancing metabolic health, dermatology, and preventative health [13]. - The digital health market is experiencing increased adoption, with a projected U.S. healthcare spending reaching $7.2 trillion by 2031 [17]. Biotech and Pet Health Platforms - Insu Therapeutics is advancing its oral insulin tablet development, targeting first-in-human studies for 2026 [19][23]. - Pawsible Ventures launched a $10 million fund to accelerate innovation in pet health, aiming to support 15-20 companies over the next three years [19]. Immersive Technology - XR Immersive Tech is expanding into health-related intellectual property, focusing on digital health applications and patient education [20][24]. - Current development areas include digital twin models for chronic-condition tracking and immersive patient engagement tools [21][27]. Additional Notes - Victory Square manages a diversified portfolio of over 20 companies across various sectors, including digital health, AI, and climate tech [26][35]. - The company is actively reviewing monetization opportunities for non-core assets, including a recent Normal Course Issuer Bid allowing the repurchase of up to 5 million common shares [26].

Core Viewpoint - Victory Square Technologies Inc. reported solid financial results for Q1 2025 and emphasized its strategic focus on the digital health and wellness sectors, identifying significant growth opportunities in a fragmented healthcare market [4][11]. Financial Highlights - Adjusted Revenue for Q1 2025 was $6.528 million, while GAAP Revenue stood at $4.540 million. The Cost of Goods Sold (COGS) was $3.036 million, resulting in a Gross Margin of $1.504 million. As of March 31, 2025, the company had Cash & Marketable Securities amounting to $9.698 million [7]. Business Focus Areas - The company aims to scale its holdings in the digital health sector, particularly through its flagship portfolio company, Hydreight Technologies, which provides a compliant platform for healthcare services across the U.S. [4][8]. - Insu Therapeutics is developing a patent-pending oral insulin tablet, with early trials showing promising results in insulin uptake [8][14]. - Pawsible Ventures is focused on pet wellness and telehealth, leveraging trends in human healthcare, with the global pet care market projected to reach $368 billion by 2030 [10][14]. Portfolio Management - Victory Square actively manages its portfolio, having sold certain AI fintech solutions for approximately $880,000 in equity consideration in Q1 2025. This follows a previous sale of BlockX for about $1.7 million in listed shares [11][15]. Industry Context - The U.S. healthcare spending exceeds $4.5 trillion annually and is projected to reach $7 trillion by 2031, highlighting the sector's fragmentation and potential for value creation [4]. - The global diabetes therapeutics market is expected to reach $118 billion by 2032, with over 500 million people currently living with diabetes [14]. Upcoming Events - Victory Square will host an Investor Webinar on July 17, 2025, to provide updates and address investor questions [12]. Leadership and Strategy - The leadership team at Insu Therapeutics includes experienced professionals from academia and the pharmaceutical industry, indicating a strong foundation for advancing its clinical milestones [14]. - The company’s business model focuses on buying, building, and investing in early-stage tech companies, with a commitment to supporting their growth for up to 48 months [17].